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  Abstract - Paroxysmal nocturnal hemoglobinuria (PNH) is a 
clonal, non-malignant, hematological disorder characterized by the 
expansion of hematopoietic stem cells and progeny mature blood 
cells which are deficient in some surface proteins, including the two 
complement regulators CD55 and CD59. PNH is the paradigm of 
diseases implying complement dysregulation as main pathogenic 
mechanism; in fact, PNH erythrocytes are uncapable to modulate on 
their surface physiologic complement activation, which eventually 
leads to the typical clinical hallmark of PNH – the chronic  
complement-mediated intravascular anemia. Indeed, due to the lack 
of CD55 complement is continuously activated on erythrocyte 
surface, which subsequently enables the terminal lytic complement 
because of the lack of CD59, finally resulting in erythrocyte lysis. 
The availability of eculizumab as the first complement inhibitor for 
clinical use renewed the interest for this rare hematological disease. 
Indeed, in the last decad the anti-C5 monoclonal antibody has 
proven effective for the treatment of PNH, resulting in a sustained 
control of complement-mediated intravascular hemolysis, with a 
remarkable clinical benefit. Anti-complement treatment allowed 
transfusion independence in at least half of PNH patients receiving 
eculizumab, with adequate control of all hemolysis-associated 
symptoms even in almost all remaining patients. In addition, the risk 
of thromboembolic events – an other clinical hallmark of PNH, 
which significantly affects prognosis and survival – seems 
substantially reduced on eculizumab treatment, apparently resulting 
in improved survival. Even with all these remarkable effects, 
eculizumab treatment does not result in hemoglobin normalization, 
and most patients remain anemic. It has been demonstrated that this 
is due to persistent activation of the early phases of complement 
activation (upstream the C5), leading to complement-mediated 
extravascular hemolysis. Ongoing researches are focusing on 
possible strategies to improve current anti-complement therapies, 
aiming to develop second-generation complement therapeutics. Here 
we review PNH and its complement-mediated pathophysiology, 
summarizing available data on anti-complement treatment; we’ll 
also discuss recent pathogenic insights which drive the development 
of novel strategies of complement inhibition. 
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I.  INTRODUCTION 
  
PNH is a rare and puzzling hematological disorder 
clinically characterized by the triad of bone marrow 
failure, severe thrombophilia and complement-mediated 
intravascular hemolysis [1-4]; the most evident sign of 
this latter manifestation (namely the hemoglobinuria 
resulting from intravascular hemolysis) accounts for the 
picturesque name of the disease. A part from its clinical 
manifestations, PNH is a unique disease of the 
hematopoiesis characterized by the expansion of a few (or 
even one) mutated hematopoietic stem cells (and progeny 
mature blood cells) carrying the bizarre phenotype of the 
lack of several proteins from their surface [5-7].   
All the proteins missing from the PNH cell surface 
share a unique biochemical feature [8]; in fact, they are 
not trans-membrane proteins, rather are linked to the cell 
membrane via a glycolipidic anchor – the glycosyl 
phosphatidyl-inositol (GPI)-moiety [9,10].  In the ‘90s, it 
has been documented that the reason accounting for this 
aberrant phenotype is a mutation in the X-linked 
phosphatidylinositol glycan class A (PIG-A) gene [11,12], 
which is necessary for the biosynthesis of the GPI-anchor. 
PNH is therefore an acquired genetic blood disorder, that 
cannot be transmitted to the progeny; however, a number 
of observations supports the concept that the mutation 




II. THE PATHOPHYSIOLOGY OF PNH 
 
PNH as a disorder of hematopoiesis 
It has been demonstrated that a few PNH-like cells 
carrying inactivating PIG-A mutations may be detected 
even in normal individuals (without any sign or symptom 
of PNH) [13].  On the other hand, the mutation does not 
reproduce the human disease in murine models; even if 
mice having a substantial proportion of PNH cells can be 
generated by using a complex technology (a conditional 
inactivation of the murine pig-a gene implemented using 
Cre recombinase specifically targeted to the hematopoietic 
stem  cells [14],    they do not really  mimic  the disease 
phenotype seen in humans, because PNH hematopoiesis 
tends to decrease over time [15].  This background raised 
the hypothesis of a dual pathophysiology for PNH (also 
known  as  the  “relative  advantage”  [16]  or “escape” 
theory [17]: the PIG-A mutation is not sufficient to cause 
the disease, and requires a second, independent event [18]. 
According to this view, a mutation in the PIG-A gene 
might be a fairly common phenomenon, with no major 
biological consequences, because in physiological 
conditions the mutated cell has no reason for expanding in 
the presence of a vast majority of normal cells. However, 
additional factors may alter this equilibrium, creating the 
conditions for the expansion of PNH clone(s); the most 
likely second event(s) is thought to be an (auto)-immune 
attack against hematopoiesis, as supported by the well-
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known clinical overlap between PNH and aplastic anemia 
(AA, which is in most cases immune-mediated) [19], as 
well as by direct demonstration of immune abnormalities 
in PNH patients [20].   
It has been recently demonstrated that the GPI-
anchor itself could be the target of such autoimmune 
attack, which would clearly spare PNH cells accounting 
for their relative expansion over normal hematopoiesis 
[21]. This pathogenic mechanisms accounts also for the 
one of typical manifestation of PNH – the moderate-to-
severe bone marrow failure.  
The other two typical features of PNH – 
intravascular hemolysis and thrombophilia – implies 
different specific pathogenic mechanisms. While the 
reasons for thrombophilia remain not fully understood and 
will not be discussed here (even if they are closely 
embedded with complement activation and hemolysis), 
the pathogenic meccanism accounting for hemolysis in 
PNH has been elucidated in details.  
 
Complement dysregulation in PNH  
The complement system is a key component of 
innate immunity evolved to recognize and to protect the 
host from both exogenous pathogenic microorganisms as 
well as injured self tissues. The complement system uses a 
number of plasma proteins , which may activate in the 
fluid phase along three distinct functional pathways – 
classical, alternative or lectin –, all finally merging into 
the a common final effector mechanism usually playing at 
a tissue level, the cytolytic membrane attack complex 
(MAC). Fluid-phase components (such as complement 
factor I [FI] and factor H [FH]) and  membrane-bound 
proteins (such as complement receptor 1 [CR1], 
membrane cofactor protein [MCP], CD55 and CD59) 
have evolved as regulatory mechanisms tuning the 
complement system in specific conditions; it is now 
understood that possible derangements of these 
physiological regulatory mechanisms may lead to specific 
human diseases [22,23].  Historically, PNH is maybe the 
first disease in whom the complement cascade has been 
demonstrated as the key pathogenic mechanism. 
As introduced above, among the several proteins 
lacking on PNH erythrocytes there are the two GPI-linked 
complement regulators CD55 and CD59.  CD55, (also 
known as Decay Accelerating Factor, DAF; [6,24] is a 70-
kd protein which inhibits the formation and the stability of 
C3 convertase (both C3bBb and C4b2a, alternative and 
classical pathways, respectively) [25]. Historically, CD55 
was the first complement regulator found absent on PNH 
erythrocytes [6,26,27], leading to the hypothesis that its 
lack could account for the increased susceptibility of PNH 
erythrocytes to complement mediated lysis. However, 
further studies demonstrated that factors other than CD55 
also were involved, likely acting downstream in the 
complement cascade [8,28].   Subsequently, CD59 (or 
Membrane Inhibitor of Reactive Lysis, MIRL; [29,30]) 
was identified as the key complement inhibitor which was 
found deficient on PNH cells [29].  CD59 interferes with 
the terminal effector complement, blocking the 
incorporation of C9 onto the C5b-C8 complex, thus 
preventing MAC formation [31].   
The hierarchical contribution of CD55 and CD59 to 
hemolysis suggests that CD59 is the pivotal molecule 
which, if absent, results into lysis [32].  This is also 
supported by the observation that subject with isolated 
deficiency of CD55 (the so-called Inab phenotype) usually 
do not show any clinical or laboratory hemolysis in vivo 
(this may be due to redundant regulatory mechanisms, 
including CD59 itself) [33,34], whereas anecdotic cases of 
inherited CD59 deficiency harbor a clinical phenotype 
undistinguishable from PNH [35,36].   
The in vitro susceptibility of PNH erythrocytes has 
been initially described by Dr. Ham in his seminal studies 
started almost a century ago. Dr. Ham demonstrated that 
erythrocytes from PNH patients lyse in autologous serum 
upon complement activation by acidification, using a 
hemolytic assay which take his own name (the Ham test, 
also known asthe acidified serum assay [37]). This feature 
of PNH erythrocytes was subsequently described more in 
depth by Dr. Rosse and Dr. Dacie, who showed that 
distinct phenotype of PNH erythrocytes may exist, 
according to their specific sensitivity to complement-
mediated lysis in vitro [38,39].   In fact, in PNH one may 
find erythrocytes with a dramatic hypersensitivity to 
complement-mediated lysis (15-25 times the normal one), 
or just a moderate hypersentivity (3-5 times normal). 
These phenotypes are referred now as PNH type III and 
type II, respectively [38,39], which by flow cytometry 
correspond to a complete (type III) or partial (type II) 
deficiency of GPI-APs respectively [40].  While the in 
vitro susceptibility of PNH erythrocytes has been 
extensively elucidated, the actual mechanisms leading to 
complement activation in vivo and subsequent hemolysis 
have not been definitely demonstrated. However, it is 
conceivable that chronic hemolysis of PNH is due to a 
continuous steady-state complement activation coming 
from the low-grade spontaneous C3 tick over, with 
subsequent continous activation of the complement 
alternative pathway (CAP) on PNH erythrocyte surface 
[41,42].  Infections or inflammatory status usually result 
in hemolytic crises (the so-called paroxysms), eventually 
as a result of massive complement activation. At the 
moment, it is not clear which pathway accounts for 
complement activation in each of these specific 
conditions, even if it is conceivable that all the three 
pathways may co-operate, possibly with some hierarchical 
dominance of the CAP, which is specifically uncontrolled 
due to CD55 deficiency, and may amplify any initial 




III. ANTI-COMPLEMENT TREATMENT IN PNH 
 
Clinical results of eculizumab in PNH 
Eculizumab (h5G1.1-mAb) is a humanized 
monoclonal antibody (mAb) [43] derived from the murine 
anti-human C5 mAb; it binds to the complement 
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component 5 (C5) and inhibits its further cleavage into 
C5a and C5b, disabling the progression to the terminal 
effector complement MAC [44].  Initial translation plans 
for eculizumab (Soliris®, Alexion Pharmaceuticals) 
started in autoimmune diseases; however, given its well-
proven complement-mediated pathophysiology, PNH was 
subsequently identified as the best disorder for 
investigating this first complement inhibitor in humans. 
The prediction was that eculizumab in PNH, by 
preventing MAC assembly, could compensate for the 
absence of CD59 on PNH erythrocytes, preventing their 
intravascular lysis upon complement activation.  
The initial phase II pilot study conducted on eleven 
heavily transfusion dependent PNH patients showed that 
eculizumab treatment was safe and well tolerated, and 
provided the proof-of-principle of effective blockade of 
intravascular hemolysis, as shown by substantial reduction 
of LDH level [45]. Eculizumab was administered 
intravenously dosed at 600 mg weekly for four weeks 
(loading phase), followed one week later by 900 mg 
fortnightly (maintenance phase); all patients were 
vaccinated against Neisseria Meningiditis at least two 
weeks before starting the treatment.  
The subsequent study was a large double-blind, 
placebo-controlled, multinational randomized trial which 
enrolled 86 transfusion-dependent PNH patients [46].  
Treatment with eculizumab resulted in a dramatic 
reduction of intravascular hemolysis, as measured by 
LDH, leading to hemoglobin stabilization and transfusion 
independence in about half of the patients. Control of 
intravascular hemolysis was found in all patients, and 
even cases not achieving transfusion independence 
showed a reduction of their transfusional needs and the 
disappearance of most clinical symptoms of hemolysis 
(painful abdominal crises, smooth muscle dystonia, 
erectile dysfunction). The effects of eculizumab on 
hemolysis were evident since the initial administration, 
and lasted for the whole study period. In comparison to 
placebo, eculizumab also resulted in a significant 
improvement in fatigue and quality of life, as measured by 
validated questionnaires. The study also showed that 
eculizumab treatment was extremely safe, with negligible 
side effects and incidence of adverse events comparable to 
that of the placebo.  
These data were confirmed in another large open-
label phase III study SHEPHERD, which enrolled a 
broader PNH population including patients with moderate 
marrow failure and minimal transfusion requirement [47].  
Based on the 96 patients enrolled in the study, treatment  
with eculizumab resulted in a remarkable control of 
intravascular hemolysis, regardless of the pretreatment 
transfusion requirement; transfusion independence was 
achieved in about half of the patients, with significant 
improvement in fatigue and quality of life in all treated 
patients [47].   
These two initial studies were continued in a 
common open-label Extension study, which included a 
total of 187 patients who have previously completed one 
of the parent clinical trials [48]. The Extension study 
confirmed the efficacy and the safety of eculizumab with a 
longer follow up, demonstating that the effects of 
eculizumab treatment on intravascular hemolysis were 
retained over time, and long-term safety remained 
excellent.   
The Extension study also looked to additional 
clinically relevant endpoint, such as the incidence of 
thromboembolicevents. By comparing the rate of 
thrombosis between the pretreatment and treatment 
periods in the same patients, the Extension study showed a 
85% reduction of the incidence of thrombosis in 
comparison to the pre-treatment period [48].  Whether 
eculizumab exerts its effect on thrombophilia of PNH 
directly (the pathophysiologyof thrombosis in PNH is still 
debated), or through the blockade of intravascular 
hemolysis (e.g., by reduction of nitric oxyde consumption 
or reduced release of procoagulant microvesicles), is still 
unknown.  However, the effects of eculizumab on 
thrombophilia of PNH seem quite specific, given that 
distinct biomarkers of coagulation pathway activation, 
reactive fibrinolysis and endothelial cell activation 
decrease during eculizumab treatment [49].  Sustained 
safety and efficacy of eculizumab was confirmed again in 
a recent report which ruled out the risk of cumulative 
toxicity [50]. Given that nowadays the median survival of 
PNH patients not receiving specific treatment is estimated 
in 22 years, it is not yet time for a robust analysis 
assessing the effect of eculizumab on survival. However 
recent data in a limited cohort of patients provid evidence 
that continuous eculizumab treatment may result in an 
improvement of survival of PNH patients [51], at least as 
compared to historical data [52]. 
 
Unmet medical needs in current treatment for PNH 
The availability of eculizumab represented a 
remarkable breakthrough in PNH therapy, which has 
dramatically impacted the natural history of the disease. 
Rarely in medicine a single agent has changed so quickly 
and so effectively the treatment of a disease, especially of 
such a rare disease; however, as always in medicine, there 
are still clinical needs which remain unmet in PNH 
regardless of eculizumab. In fact, even if eculizumab 
results in an adequate control of intravascular hemolysis 
in most (if not all) PNH patients for whom anti-hemolytic 
treatment is indicated (eculizumab is not indicated in PNH 
patients with bone marrow failure, where anemia is mostly 
due to impaired red cell production rather than to 
hemolysis), the majority of patients continue to harbor 
mild-to-moderate anemia. Eculizumab also represented a 
unique opportunity for a better understanding of PNH 
pathophysiology in absence and in presence of clinical 
anti-complement (anti-C5) inhibition, allowing the 
dissection of the pathogenic contribution of the different 
phases of complement cascade which remain uncontrolled 
in PNH.  We have demonstrated that additional 
mechanisms of disease may account for residual anemia 
seen in PNH patients during eculizumab treatment. 
Indeed, PNH erythrocytes survive to complement 
activation because of the sustained inhibition of the 
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terminal effector complement – C5 cleavage and 
subsequent MAC assembly; however, they may 
progressively become decorated on their surface by C3 
fragments, which may eventually work as opsonins with 
subsequent entrapment of C3-bound PNH erythrocytes in 
the hepatosplenic macrophages. We have documented the 
phenomenon of C3 deposition by flow cytometry in all of 
our initial 41 PNH patients on eculizumab, whereas 15 
untreated PNH patients do not show any C3+ erythrocyte 
[53].   
The proportion of C3+ PNH erythrocytes is 
heterogeneous among patients, and in some way may 
correlate with the hematologic response during 
eculizumab treatment, as subsequently confirmed by 
another group [54]. In fact, we have also observed that 
most PNH patients on eculizumab remain anemic, 
regardless of an adequate control of intravascular 
hemolysis (as shown by normal or almost normal LDH 
levels), and all of them continue to have substantial 
reticulocytosis [53].  Thus, we came to the conclusion that 
eculizumab treatment may result in a complete control of 
the intravascular hemolysis typical of PNH, but in some 
patients may unmask a novel mechanism of disease, 
which is C3-mediated extravascular hemolysis.  This 
working hypothesis was supported by the observation that 
these patients also have persistent reticulocytosis, 
hyperbilirubinemia and anemia, and it was definitely 
confirmed by an in vivo erythrocyte survival study by 
51
Cr 
labeling, which in paradigmatic cases showed reduced 
survival and hepatosplenic 
51
Cr uptake [53].   
The observation of clinically remarkable C3-
mediated extravascular hemolysis in PNH patients on 
eculizumab was for sure disappointing, but it is not 
necessarily detrimental to eculizumab. The reasons 
underlying this phenomenon are not related to eculizumab 
itself, rather they are linked to the absence of CD55 on 
PNH erythrocytes, accounting for persistent uncontrolled 
C3 convertase activation even regardless of the terminal 
complement inhibitor eculizumab (which acts downstream 
in the complement cascade). Indeed, it is only when 
eculizumab prevents MAC-mediated intravascular 
hemolysis that PNH erythrocytes survive longer enough to 
become susceptible to C3-fragment opsonization, and 
possible subsequent hemolysis through the C3-specific 
receptors expressed on reticuloendothelial cells (because 
even massive C3 activation does not lead to MAC 
assembly and lysis) [55,56].   
It is not entirely clear why this mechanism of disease 
remains subclinical in some patients (who only have 
minimal residual anemia and persistent reticulocytosis) 
and led to a remarkable anemia in other cases; preliminary 
data suggest that genetic heterogeneity in other 
physiological modulators of complement activity (e.g., 
CR1) may account for higher risk of residual anemia 
during eculizumab treatment [57]. Nevertheless, it is 
conceivable that continuous uncontrolled complement 
activation through the alternative pathway is the ultimate 
cause of this phenomenon. In fact, CAP is physiologically 
in a state of continuous activation because of the C3 tick-
over (a low-grade, spontaneous hydrolysis of the internal 
thioester bond of C3) generating a C3b-like molecule, 
C3(H2O); nascent C3(H2O) is able to recruit factor B in 
forming (in the fluid phase) an unstable pro-C3 
convertase. Once cleaved by factor D (generating 
C3(H2O)Bb), this complex will in turn cleave additional 
C3 molecules to generate C3b, which binds predominantly 
to glycophorin A and activates (now in a membrane-
bound phase on erythrocytes) the CAP amplification loop 
[22,58,59].  As stated above, this process is finely 
regulated by CD55, which is absent on PNH erythrocytes; 
thus, early complement activation is self-limiting on 
normal cells, but it eventually leads to progressive CAP-
mediated amplification on PNH erythrocytes, regardless 
of the presence of eculizumab (which acts downstream 
C3).  
The reasons why only a fraction of PNH erythrocytes 
has membrane-bound C3, and why the proportion varies 
among patients, are not fully understood, even if in vitro 
data support the concept that PNH erythrocytes are all 
susceptible to C3 deposition once exposed to conditions 
causing complement activation [60].  Our current 
understanding is that each individual erythrocyte has to 
reach a specific threshold needed to start CAP activation, 
and that in vivo only a small fraction of erythrocytes is 
exposed to such a threshold, possibly as a result of 
specific microenvironmental conditions generating in 
particular vascular districts (this may open a possible 
similarity with the site-specific risk of thrombotic events), 
or simply stochastically. However, even assuming as well-
established the mechanism leading to C3 decoration on 
PNH erythrocytes, their subsequent clearance through the 
reticuloendothelial system remains to be elucidated. In 
fact, it is not clear why some patients do not show 
clinically relevant extravascular hemolysis regardless of a 
large proportion of C3-bound PNH erythrocytes [56].  
Neverthless, residual anemia during eculizumab treatment 
is an emerging clinical need in PNH, which so far has no 
adequate treatment option. In fact, steroids are not useful 
and should be avoided [56], and splenectomy may 
represent an option [61], but it is not routinely 
recommended given its considerable medical risks, such 
as intra- or peri-operatory thrombotic complications and 
life-long infectious events [62].  Furthermore, long-lasting 
continuous extravascular hemolysis might lead to 
additional long-term complications such as gallstone 
formation or iron overload [63], possibly requiring further 




IV. DEVELOPMENT OF NOVEL ANTI-
COMPLEMENT STRATEGIES IN PNH 
 
The observation that early phases of the complement 
cascade, and in particular C3 activation, represent a 
common biological event possibly resulting in clinical 
consequences remarks the need of novel strategies of 
complement modulation. Thus, investigators have started 
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to think about alternative strategies to target early events 
of the complement cascade, possibly directly at the initial 
C3 activation (Figure 1).  
Neverthless, it has to be acknowledged that a broad 
C3 inhibition would carry substantial safety concerns, 
given that inherited C3 deficiency is associated with a 
remarkable risk of developing both severe infectioins and 
autoimmune diseases [64]. Ideally, one would like 
delivering a complete inhibition of the complement 
activation occurring on erythrocyte surface due to the lack 
of the complement inhibitors CD55 and CD59, possibly 
retaining at least part of the physiological role of the 
complement in the clearance of microorganisms and 
injured tissues. In keeping with the terrific clinical results 
of the anti-C5, different anti-C3 mAb have been initially 
considered, aiming to bind native C3 in the fluid phase 
preventing its activation along all the three pathways; 
however, this approach was abandoned because of the 
high plasmatic concentration of C3, which makes this 
approach quite problematic and expensive. In additional, it 
would carry several concerns because of the risk of 
possible infectious and autoimmune complications 
secondary to a complete disabling of the complement 
cascade.  
Another antibody-based anti-C3 strategy was 
developed, aiming to target activated C3 (C3b/iC3b) 
rather than the native C3 in the fluid phase. Indeed, the 
anti-C3b/iC3b murine mAb 3E7 and its chimeric-
deimmunized derivative H17 were shown to selectively  
inhibit the activity of C3 and C5 convertases of the CAP 
only, providing the opportunity for a selective inhibition 
of different complement pathway [65]. These antibodies 
were tested in vitro on PNH erythrocytes, and were shown 
effective in preventing complement-mediated hemolysis 
of CD55/CD59 deficient erythrocytes [65]. This finding 
was elegant and conceptually innovative, but likely still 
far from a clinical translation, because given that in PNH 
C3 and C5 convertases localized on erythrocyte surface, 
these antibodies would finally work as additional opsonins 
which should even increase PNH erythrocyte clearance by 
the reticuloendothelial cells, through both the C3- and Fc-
specific macrophage receptors. Indeed, before being tested 
in the clinic these antibodies should be modified by 
removing their Fc moiety; however, according to available 
information, such engineered anti-C3 mAb (or Fab 
fragments) are not available yet.   
More recently, we and others have developed a novel 
strategy of complement inhibition, which aims to deliver a 
selective (for the CAP) and targeted (on PNH 
erythrocytes) inhibition of early phases (C3 activation) of 
the complement cascade, while retaining intact the 
functioning of the other two complement pathways. This 
strategy is based on the use of an anti-complement activity 
deriving from the endogenous complement FH, modified 
by recombinant DNA technologies. FH is a physiological 
complement inhibitor that modulates the initial CAP 
activation in the fluid phase by preventing C3 convertase 
activity and by promoting C3b inactivation into iC3b [66].  
Indeed, FH defuses the CAP amplification loop (which 
starts regardless the initial pathway of complement 
activation), and it has been demonstrated protective from 
lysis for PNH erythrocytes in vitro [67].   
At least two different FH-derived agents have been 
developed. The first one has been designed by creating a 
recombinant fusion protein between complement FH and 
another complement-related protein, complement receptor 
2 (CR2).  In the aim to deliver FH activity locally at the 
site of complement activation, FH was fused with the 
iC3b/C3d-binding domain of CR2. Using C3 fragments as 
target seem quite appropriate given our observation that 
complement activation in PNH starts with surface C3-
deposition, eventually leading to intravascular hemolysis 
or, in presence of eculizumab, to possible extravascular 
hemolysis. This novel compound named TT30 was 
recently investigated by our group in an in vitro model 
based on exposure of PNH erythrocytes to CAP-activated 
serum.  We have demonstrated that TT30 completely 
inhibits complement-mediated hemolysis of PNH 
erythrocytes; in addition, it effectively prevents initial C3 
activation and further C3 deposition on PNH erythrocytes 
[68].  We were able to demonstrate the presence of TT30 
on PNH erythrocyte surface, as well as the reversion of 
the protective effect if anti-CR2 antibodies are added, 
consistent with the initial assumption that TT30 mainly 
work at the surface level, and cell membrane targeting is 
required for full inhibitory effect.  Mechanistically, as a 
FH derivative, TT30 is able to act as a cofactor for FI to 
convert nascent C3b into iC3b, thus generating more of its 
own target and disabling the CAP amplification loop. At 
the same time, TT30 serves a CD55 surrogate on PNH 
erythrocytes, preventing the formation and promoting the 
decay of the CAP C3 convertase by displacing factor B 
and factor Bb, respectively, from the C3b-bound state.  
These in vitro data support the concept that TT30 in vivo 
could be useful to prevent both intravascular and 
extravascular hemolysis of PNH erythrocytes.  
Based on this robust background, a phase I clinical 
trial has just started to enroll PNH patients in a first-in-
human study [69].  This initial trial will also be useful to 
rule our possible concerns about this more intensive 
strategy of complement inhibition: the hope is that 
physiological immune-complex clearance and 
microorganism elimination may be preserved because of 
the CAP-selective and membrane-preferential action of 
TT30. If this anticipation will be confirmed, one may 
hypothesize that TT30 will be extensively investigated in 
PNH, given that based on the in vitro data it is very likely 
that the anti-hemolytic action on PNH erythrocytes should 
be extremely effective.   
The second FH-derived recombinant protein follows 
the same idea of TT30, thus aiming to maximize FH 
activity at the sites of complement activation. Here the 
surface-recognition domain does not come from a 
different protein (e.g., CR2); rather, the FH domains 
SCR19-20 (which have a strong affinity for the opsonins 
C3b, iC3b and C3d) are utilized, in a recombinant protein 
which is called “mini-FH”. Mini-FH is an engineered 
43kDa protein that retains  both convertase decay 
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Figure 1. Complement cascade modulation on normal and PNH red blood cells (RBCs), with or without complement inhibitors. 
A. Normal RBCs: steady state. 
Normal RBCs (CD55+, CD59+) are protected from complement activation by CD55, which down-regulate the C3-convertase, and by CD59, which 
inhibits the MAC assembly. Thus, in steady state normal RBCs can withstand the challenge of complement activation. 
B. PNH RBCs: steady state. 
Given their deficiency in surface CD55, PNH RBCs are susceptible to complement activation through C3 tick-over and the alternative pathway, as well 
as through any other complement pathway. After initial C3 activation and subsequent C3b-binding to erythrocyte surface, the complement cascade may 
proceed toward the MAC formation, which is not inhibited due to the lack of CD59. As a result, PNH RBCs succumb because of MAC-mediated 
intravascular hemolysis. 
C. PNH RBCs: effect of eculizumab. 
Eculizumab binds to C5 in the fluid phase and prevents its cleavage to C5a and C5b. As a result, the progression of the complement cascade toward the 
MAC assembly is completely inhibited, and PNH RBCs result protected from MAC-mediated intravascular hemolysis. However, given the lack of 
CD55, initial CAP activation through the C3 tick-over and the CAP-mediated amplification loop remain uncontrolled; thus, early C3 activation 
continues, and because of their increased survival PNH RBCs progressively bind substantial amount of C3 fragments on their surface. Subsequently, 
C3-opsonized PNH RBCs become susceptible to C3-receptor mediated clearance by the hepato-splenic reticulo-endothelial system, eventually resulting 
in C3-mediated extravascular hemolysis. 
D. PNH RBCs: effect of C3 inhibitors. 
FH-based proteins (FH**), either TT30 or mini-FH, bind to C3b initially activated on PNH RBCs, and deliver their complement-modulatory effect via 
their FH domain.  Thus, FH-based proteins disable the C3-convertase, and, as co-factor of factor I, they also promote the conversion of active C3b into 
iC3b and then C3dg/C3d, preventing all downstream events due to the complement cascade (as well as additional complement activation on the red cell 
membrane). As a result, irrespective of the blockade of C5, C3 inhibitors may confer to PNH RBCs a normal survival even in presence of complement 
activation. All other agents acting at the level of C3 convertase (e.g., compstatin analogs) may work in a similar way, inhibiting initial complement 
activation on PNH erythrocyte surface and preventing all the downstream events leading to either intravascular or extravascular hemolysis. 
 
 
"This figure is modified from the research originally published in Blood. Risitano AM, Notaro R, Pascariello C, Sica M, Del Vecchio L, Horvath CJ, 
Fridkis-Hareli M, Selleri C, Lindorfer MA, Taylor RP, Luzzatto L, Holers VM. The complement receptor 2/factor H fusion protein TT30 protects 
paroxysmal nocturnalhemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization. Blood. 2012;119(26):6307-16. 
© the American Society of Hematology." 
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acceleration and cofactor activities typical of endogenous 
human FH, combined with an increased surface-
recognition activities, resulting in a potent and selective 
inhibition of activation and amplification of the 
complement alternative pathway, without affecting the 
classical and the mannose/lectin pathway.  This compound 
too was investigated by our group in vitro: mini-FH 
showed a dose-dependent inhibition of hemolysis, with an 
IC50 of 0.05 µM and full inhibition at 0.1 µM. Mini-FH 
also prevented surface deposition of C3 fragments on 
PNH erythrocytes. on exposure of PNH erythrocytes to 
CAP-activated serum.  Notably, mini-FH was far more 
potent of TT30, with full inhibition achieved at 
concentrations about 1 log lower than TT30 [70].   
Thus, the spectrum of complement inhibitors moved 
from monoclonal antibodies to recombinant proteins, 
which yet may carry elevated production costs (that 
hopefully will not lead to treatment cose as outrageous as 
that of eculizumab).  
However, C3-targeted complement inhibition also 
include strategies based on small peptide inhibitors, which 
potentially are more easy and more cheap to develop. 
Compstatin is a 13-residue disulphide-bridged peptide that 
selectively binds to C3 and its active fragment C3b [71]. 
Compstatin prevents the conversion of C3 to C3b and thus 
it impairs all initiation, amplification, and terminal 
pathways of the complement cascade  [72]. As a result, 
compstatin and its derivatives are considered highly 
promising candidate drugs for treating different 
complement-mediated diseases [73]. We have recently 
investigated the in vitro effects of different compstatin 
analogs; preliminary data showed that, similarly to FH-
based proteins, compstatin analogs inhibit complement 
activation on PNH erytrocytes preventing both hemolysis 
and C3-deposition on their surface [74]. Further 
preclinical investigations are currently ongoing to collect 
all the information needed to support translational plans 
for this class of agents in human diseases, including PNH. 
The list of candidate agents for novel complement 
therapeutics might be even longer, if one wish to include 
inhibitors of complement FB or FD, or of properdin, as 
well as other recombinant proteins able to tune 
complement activity (e.g., recombinant complement FI). 
As for C3 inhibitors, all these candidate agents share 
the concept that targeting early events in the complement 
cascade may be a worthy option, especially in medical 
conditions where the terminal complement blockade by 
eculizumab may result in pharmacological leaks that leads 
to clinical consequences.  
Of course the second generation complement 
inhibitors will require careful initial clinical investigations 
to assess whether such a more profound or broader 
complement inhibition will replicate the excellent safety 
profile seen with eculizumab. In fact, it will be only when 
all concerns about increased infectious and autoimmune 
risks will have been ruled out that the efficacy of this 
promising strategies could be extensively studied in PNH 





Therapeutic complement inhibition has led to 
remarkable clinical results in PNH in the last decade.  As 
long as time passes, that the lesson from PNH becomes 
more clear: the current anti-C5 agent eculizumab is safe 
and effective, but residual complement activity resulting 
from upstream complement components may account for 
suboptimal clinical results. Complement inhibition 
targeting the C3 is an emerging option to develop novel 
complement therapeutics, and hopefully will be useful to 
handle current unmet clinical needs in PNH. Different 
strategies are currently under development, and a numeber 
of candidate agents are in preclinical or even clinical 
studies; the winner will result not only from objective 
data, but also on the efforts put by the investigators and on 
the investments put by the companies (treatment cost 
remains a remarkable issue in all Countries). A novel era 
for complement modulation has just started; the challenge 
is to establish targeted and specific treatment for PNH and 
other complement-mediated diseases.  
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